Results 141 to 150 of about 43,902 (289)

The contemporary management of prostate cancer

CA: A Cancer Journal for Clinicians, Volume 75, Issue 6, Page 552-586, November/December 2025.
Abstract Prostate cancer is the most common cancer in two thirds of the world, with an expected doubling in both incidence and mortality in the next two decades. No strong environmental associations exist for the development of prostate cancer; therefore, lifestyle measures are unlikely to mitigate this increasing burden.
Deep Chakrabarti, Peter Albertsen, Aidan Adkins, Amar Kishan, Vedang Murthy, Chris Parker, Angela Pathmanathan, Alison Reid, Oliver Sartor, Nicholas Van As, Jochen Walz, Alison Tree   +11 more
wiley   +1 more source

Physiologische Konzentrationen Denosumab steigern die osteogene Differenzierung von humanen mesenchymalen Stammzellen [PDF]

, 2019
Alexander Mosch
openalex   +1 more source

The Effect of RANKL/OPG Balance on Reducing Implant Complications [PDF]

, 2017
Despite the phenomenal success of implants particularly in the realms of dentistry and orthopaedics, there are still challenges to overcome. The failure of implants resulting from infection, prosthetic loosening, and non-union continue to be the most ...
Giannoudis, P.V., Hatton, P.V., Jia, X., Kapasa, E.R., Yang, X.B.   +4 more
core   +3 more sources

Polygenic Risk Score as a Predictor of Bone Fracture or Osteoporosis in Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Cancer Medicine, Volume 14, Issue 22, November 2025.
ABSTRACT Background The association between single nucleotide polymorphisms (SNPs) and fracture risk has been established in various studies. Androgen‐deprivation therapy (ADT) for prostate cancer, while extending survival, increases the risk of osteoporosis and bone fracture.
Ying‐Qiang Liu, Li‐Wen Chang, Hui‐Wen Yang, Jian‐Ri Li, Yi‐Ming Chen, Sheng‐Chun Hung, I‐Chieh Chen   +6 more
wiley   +1 more source

Severe Hypocalcemia and Hypomagnesemia with Denosumab in Advanced Chronic Kidney Disease: Case Report and Literature Review

Case Reports in Oncological Medicine, 2018
Background. Denosumab has become the preferred agent over zolendronic acid to help prevent skeletal-related events in patients with metastatic bone disease and multiple myeloma because it is approved for use in those with kidney dysfunction.
Christina F. Marlow, Shailendra Sharma, Faizan Babar, Jianqing Lin   +3 more
doaj   +1 more source

The essential role of nuclear translocation of β-catenin in the osteoblastic differentiation of giant cell tumor of bone: Prediction of tumor ossification after denosumab treatment

, 2021
Atsushi Kimura, Yu Toda, Yoshihiro Matsumoto, Hidetaka Yamamoto, Kenichiro Yahiro, Eijiro Shimada, Masaya Kanahori, Suguru Fukushima, Makoto Nakagawa, Nokitaka Setsu, Makoto Endo, Toshifumi Fujiwara, Tomoya Matsunobu, Yoshinao Oda, Yasuharu Nakashima   +14 more
openalex   +1 more source

MO801SAFETY AND EFFICACY OF DENOSUMAB IN HEMODYALISED PATIENTS UP TO 48 MONTHS TREATMENT FOLLOW-UP [PDF]

, 2021
Rita Chiara Ierace, Alessandra Moioli, Francescaromana Festuccia, Claudia Fofi, Simona Barberi, Paolo Mené   +5 more
openalex   +1 more source

Single-cell transcriptome analysis reveals T-cell exhaustion in denosumab-treated giant cell tumor of bone

, 2022
Meiling Yang, Fen Wang, Guohao Lu, Mingzhe Cheng, Wei Zhao, Changye Zou   +5 more
openalex   +1 more source

Guided Bone Regeneration (GBR) for Reconstructing Alveolar Bone Defects Following Resective Treatment of Medication‐Related Osteonecrosis of the Jaws (MRONJ) Lesions: A Case Series

Clinical Case Reports, Volume 13, Issue 11, November 2025.
This composite figure illustrates some of the clinical and radiographic features of medication‐related osteonecrosis of the jaw (MRONJ), including panoramic, intraoral, axial CBCT, and extraoral images highlighting intra‐oral to bone probing, radiographic lysis, sequestration and periosteal reaction, and facial swelling.
Daya Masri, Omar Ghanaiem, Vadim Raiser, Shaked Adut, Gavriel Chaushu   +4 more
wiley   +1 more source

Safety and Efficacy of Denosumab for Fibrous Dysplasia of Bone.

New England Journal of Medicine, 2023
L. F. de Castro, Z. Michel, Kristen S. Pan, Jocelyn Taylor, V. Szymczuk, S. Paravastu, B. Saboury, G. Papadakis, Xiaobai Li, Kelly Milligan, BrendanF. Boyce, S. Paul, Michael T. Collins, A. Boyce   +13 more
semanticscholar   +1 more source